Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial.
Schizophrenia is a symptomatically heterogeneous disorder characterized by the presence of positive and negative symptoms, and variable impairment in community functioning. Given the diversity of symptom presentations and functioning associated with schizophrenia, one of the key challenges facing the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial was the selection of efficient assessment measures appropriate to a community-based effectiveness trial. This article describes the rationale for the measurement approach adopted for the trial, provides a brief overview of the selected measures, and describes the process of training assessment raters for a large and geographically dispersed study group.
Swartz
Marvin S
MS
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Box 3173, Durham, NC 27710, USA. marvin.swartz@duke.edu
Perkins
Diana O
DO
Stroup
T Scott
TS
McEvoy
Joseph P
JP
Nieri
Jennifer M
JM
Haak
David C
DC
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001294:Attitude to Health; D002986:Clinical Trials as Topic; D003863:Depression / Q000175:diagnosis; D039721:Diagnostic and Statistical Manual of Mental Disorders; D006801:Humans; D008019:Life Style; D010043:Outcome and Process Assessment, Health Care; D011595:Psychomotor Agitation / Q000175:diagnosis; D011788:Quality of Life; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D019966:Substance-Related Disorders / Q000175:diagnosis; D011795:Surveys and Questionnaires
D014150:Antipsychotic Agents